ImmunityBio launches phase 2 trial of ANKTIVA for long COVID treatment
Tweet Send to a Friend
ImmunityBio Inc. (NASDAQ: IBRX) announced the initiation of a Phase 2 clinical study evaluating ANKTIVA for treating long COVID, a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
